HOPE RESEARCH CENTER HAS NEW PUBLICATION ON THE LANCETApr 23rd, 2021
In infertile couples with non-male factor infertility, would intracytoplasmic sperm injection (ICSI) result in a higher live birth rate compared with conventional in vitro fertilization (c-IVF) ?
This question has been addressed in a recent publication by HOPE Research Center on The Lancet, 24 April issue (2021).
In a multicenter, randomized controlled trial (RCT) on 1,064 couples, the authors found that live birth after the first embryo transfer and cumulative ongoing pregnancy resulting in live birth at 12 months after randomization from the initiated cycle were similar in couples undergoing ICSI compared with c-IVF (35% vs. 31%, RR 1.11, 95% CI 0.93 to 1.32 and 42% vs. 41%, RR 1.02, 95% CI 0.89 to 1.18; respectively), despite the risk of having no embryos to transfer being significantly lower in the ICSI group (2% vs. 4%, RR 0.38, 95% CI 0.17 to 0.85).
This is the largest randomized trial to date and the first to provide data on live birth after the use of ICSI versus c-IVF in couples with non-male factor infertility. These results challenge the value of the routine use of ICSI in assisted reproduction techniques for this population. Preliminary data of this study has been presented at ESHRE 2020.
This project was sponsored by HOPE Research Center, My Duc Hospital and Merck Sharpe and Dohme, in collaboration with An Sinh Hospital, The University of Medicine and Pharmacy at Ho Chi Minh City (Viet Nam), The Monash University and The University of Adelaide (Australia).